Ipsirius
Ipsirius
  • Home
  • About Us
  • Science
  • Pipeline
  • Investors
    • Investor Home
    • Educational Resources
    • Clinical Development
    • Intellectual Property
    • Regulatory & Compliance
    • Partners & Alliances
    • Funding Diversification
    • Market Assessment
  • News
  • Publications
  • Careers
  • Contact Us
  • More
    • Home
    • About Us
    • Science
    • Pipeline
    • Investors
      • Investor Home
      • Educational Resources
      • Clinical Development
      • Intellectual Property
      • Regulatory & Compliance
      • Partners & Alliances
      • Funding Diversification
      • Market Assessment
    • News
    • Publications
    • Careers
    • Contact Us
  • Sign In
  • Create Account
  • My Account

  • Signed in as:

  • filler@godaddy.com

  • My Account

  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • About Us
  • Science
  • Pipeline
  • Investors
    • Investor Home
    • Educational Resources
    • Clinical Development
    • Intellectual Property
    • Regulatory & Compliance
    • Partners & Alliances
    • Funding Diversification
    • Market Assessment
  • News
  • Publications
  • Careers
  • Contact Us

Account

  • My Account

  • Sign out

  • Sign In
  • My Account

ABOUT US

iPSirius, a French biotechnology company that originated from INSERM and Paris Saclay University, has set its ambition on developing active cancer immunotherapy products. Their focus lies in utilizing groundbreaking induced pluripotent stem cell (iPSC) technology. iPSirius successfully developed its first therapeutic product known as IPVAC 1.0, with the objective of priming the patient's own immune system against a wide range of cancer targets.

Our Vision

Our vision is to improve prognosis of cancer patients by bringing transformational and valued therapies addressing metastasis and treatment resistance. This year we conducted an exploratory road trip where we engaged investors as to the indication for our first in human (FIH) clinical trial. We are currently in the planning phases for our FIH trial for IPVAC 1.0 which will be conducted in the UK.

Executive Team

Frank Griscelli, PhD

Ali Turhan, MD, PhD

Frank Griscelli, PhD

 Chief Pharma Officer

View Bio

Annelise Bennaceur, MD, PhD

Ali Turhan, MD, PhD

Frank Griscelli, PhD

 Chief Scientific Officer 

View Bio

Ali Turhan, MD, PhD

Ali Turhan, MD, PhD

Ali Turhan, MD, PhD

 Chief Medical Officer 

View Bio

Stephen Sullivan, PhD, MBA

Stephen Sullivan, PhD, MBA

Ali Turhan, MD, PhD

 Chief Operating Officer 

View Bio

Bertrand Roux de Luze, MBA

Stephen Sullivan, PhD, MBA

Bertrand Roux de Luze, MBA

 Chief Financial Officer 

View Bio

Advisors

Jaqueline Barry, PhD

Jean-Hugues Trouvin, PharmD, PhD

Jaqueline Barry, PhD

Clinical and regulatory activities 

Marc Turner, MD, PhD

Jean-Hugues Trouvin, PharmD, PhD

Jaqueline Barry, PhD

Clinical safety and manufacture

Jean-Pierre Armand, MD, PhD

Jean-Hugues Trouvin, PharmD, PhD

Jean-Hugues Trouvin, PharmD, PhD

Industrialization

Jean-Hugues Trouvin, PharmD, PhD

Jean-Hugues Trouvin, PharmD, PhD

Jean-Hugues Trouvin, PharmD, PhD

Regulatory affairs 

Jean Loup Romet-Lemonne, MD, PhD

Jean Loup Romet-Lemonne, MD, PhD

Jean Loup Romet-Lemonne, MD, PhD

  Value proposition 

and market

Tanguy Nicolet, LLM

Jean Loup Romet-Lemonne, MD, PhD

Jean Loup Romet-Lemonne, MD, PhD

  Legal affairs and IP

Our Partners

Connect with us!

Copyright © 2023 Ipsirius - All Rights Reserved.

Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept